RTALB.E — RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapSucker Stock

Market Cap
TRY1.29bn
Enterprise Value
TRY1.21bn
Revenue
TRY86.03m

Annual income statement for RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	R2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	20.5	16.8	230	384	86
Cost of Revenue
Gross Profit	2.8	4.28	111	156	34.8
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	30.9	19.4	181	292	42.6
Operating Profit	-10.4	-2.62	49.3	92.7	43.4
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.23	3.95	88	147	302
Provision for Income Taxes
Net Income After Taxes	1.27	4.57	78.4	127	288
Minority Interest
Net Income Before Extraordinary Items
Net Income	2.2	4.42	60.9	114	281
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2.2	4.42	60.9	114	281
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.079	0.07	0.937	1.21	2.81
Dividends per Share